Refine
Is part of the Bibliography
- yes (417)
Year of publication
Document Type
- Journal article (217)
- Doctoral Thesis (195)
- Conference Proceeding (3)
- Book (1)
- Preprint (1)
Keywords
- Virologie (37)
- HIV (33)
- Masernvirus (29)
- T-Lymphozyt (24)
- measles virus (22)
- Immunologie (18)
- Dendritische Zelle (15)
- Masern (14)
- T cells (14)
- Apoptosis (13)
- dendritic cells (13)
- regulatory T cells (12)
- HIV-Infektion (11)
- Ratte (11)
- Spumaviren (11)
- Immunsuppression (10)
- SARS-CoV-2 (10)
- measles (10)
- Apoptose (8)
- CD28 (8)
- apoptosis (8)
- Antigen CD8 (7)
- B-Lymphozyt (7)
- Lymphozyt (7)
- Maus (7)
- rat (7)
- Antigen CD28 (6)
- Blimp-1 (6)
- Coronaviren (6)
- Immunaktivierung (6)
- Immunreaktion (6)
- Interferon (6)
- Retroviren (6)
- Signaltransduktion (6)
- Virusinfektion (6)
- autoimmunity (6)
- foamy virus (6)
- immunosuppression (6)
- AIDS (5)
- Autoimmunität (5)
- Gentherapie (5)
- Glucocorticosteroide (5)
- Immunsystem (5)
- Infektion (5)
- Regulatorischer T-Lymphozyt (5)
- T-Zellen (5)
- Treg (5)
- Virus (5)
- ceramide (5)
- immune evasion (5)
- interferon (5)
- Antikörper (4)
- CD150 (4)
- CD1d (4)
- COVID-19 (4)
- Dendritische Zellen (4)
- EAE (4)
- Encephalitis (4)
- Foamyviren (4)
- Immunisierung (4)
- Immuntoleranz (4)
- Impfung (4)
- Medizin (4)
- Multiple Sklerose (4)
- Polymerase-Kettenreaktion (4)
- Prednisolon (4)
- Prion (4)
- T cell (4)
- T cell receptor (4)
- T-Zelle (4)
- Tansania (4)
- Tiermodell (4)
- Toleranz (4)
- Vektor <Genetik> (4)
- Viren (4)
- cell staining (4)
- ceramides (4)
- dendritic cell (4)
- infection (4)
- macrophages (4)
- monocytes (4)
- multiple sclerosis (4)
- regulatorische T-Zellen (4)
- reverse transcriptase (4)
- sphingolipids (4)
- sphingomyelinase (4)
- tolerance (4)
- virus (4)
- APOBEC3G (3)
- Adenoviren (3)
- Affenimmundefizienzvirus (3)
- Aktivierung <Physiologie> (3)
- Antigen CD22 (3)
- Avidität (3)
- B-Zellen (3)
- CD22 (3)
- Candida albicans (3)
- Ceramid (3)
- Coronavirus (3)
- Dendritic cells (3)
- Foamyvirus (3)
- GFAP (3)
- Genexpression (3)
- HIV-1 (3)
- Immunmodulation (3)
- Immunology (3)
- Interferon <gamma-> (3)
- Interleukin 2 (3)
- Kostimulation (3)
- Monoklonaler Antikörper (3)
- Parkinson (3)
- Parkinson’s disease (3)
- Pathogenese (3)
- Polyomaviren (3)
- Prionprotein (3)
- Proliferation (3)
- RNS (3)
- RNS-Interferenz (3)
- Replikation (3)
- Resistenz (3)
- South Africa (3)
- Sphingomyelinphosphodiesterase (3)
- T cell activation (3)
- TNF-alpha (3)
- Tanzania (3)
- Toll-like-Rezeptoren (3)
- Tumor-Nekrose-Faktor <alpha> (3)
- acid sphingomyelinase (3)
- antibodies (3)
- antiretroviral therapy (3)
- encephalitis (3)
- evolution (3)
- flow cytometry (3)
- foamyvirus (3)
- gene expression (3)
- gene therapy (3)
- herpesvirus (3)
- human (3)
- immune activation (3)
- immunology (3)
- neuroprotection (3)
- phosphoantigen (3)
- phylogenetic analysis (3)
- prion protein (3)
- regulatorische T Zellen (3)
- replication (3)
- sphingosine-1-phosphate (3)
- virology (3)
- 3D tissue model (2)
- A1 (2)
- Antigen CD4 (2)
- Atemwegsinfektion (2)
- Autoantikörper (2)
- Autoimmunerkrankung (2)
- Autoimmunity (2)
- B cells (2)
- B-cell (2)
- BTN3 (2)
- Baumwollratte (2)
- Bcl-2 (2)
- Bcl-2 Familie (2)
- Bcl-2 family (2)
- Behandlung (2)
- CD28 Superagonist (2)
- CD28 superagonist (2)
- CD4(+) (2)
- CD40 (2)
- CD46 (2)
- CD8 T-Zellen (2)
- CMV (2)
- CTLA-4 (2)
- Ceramide (2)
- Chemotaxis (2)
- Children (2)
- CpG-ODN (2)
- Cytomegalie-Virus (2)
- D665 (2)
- Demenz (2)
- Dendritic cell (2)
- Dopamin (2)
- EBV (2)
- Elite Controller (2)
- Epidemiologie (2)
- Foamy virus (2)
- Glykoproteine (2)
- HAART (2)
- HAND (2)
- HHV-6 (2)
- HIVDR (2)
- Herpes (2)
- Homologe Rekombination (2)
- Human papillomavirus (2)
- Hybridvektor (2)
- IL1RA (2)
- ISGF3 (2)
- ISRE (2)
- Immunbiologie (2)
- Immunstimulation (2)
- Impfstoff (2)
- Inhibition (2)
- KDELR2 (2)
- KLRG1 (2)
- ME/CFS (2)
- MLR (2)
- Makrophagen (2)
- Matrix-Protein (2)
- Matrixproteine (2)
- Measles (2)
- Medicine (2)
- Memantin (2)
- Molekularbiologie (2)
- Natürliche Killerzelle (2)
- PVM (2)
- Parkinson-Krankheit (2)
- Persistenz (2)
- Polyadenylierung (2)
- Polyoma-Virus (2)
- Polyomavirus WU (2)
- Proteasen (2)
- Proteine (2)
- Proteinkinase B (2)
- RNA (2)
- RNA interference (2)
- RNA polymerase II (2)
- RS-Virus (2)
- RSV (2)
- Regulatorische T-Zellen (2)
- Reverse Transkriptase (2)
- Rezeptor (2)
- Rheumatoide Arthritis (2)
- SLAM (2)
- SSPE (2)
- Sindbisvirus (2)
- Sphingolipide (2)
- Sphingomyelin (2)
- Spumaviruses (2)
- Staupevirus (2)
- T Zellen (2)
- T cell development (2)
- T cell receptors (2)
- T-Helferzellen (2)
- T-Lymphozyten-Rezeptor (2)
- T-Zell-Aktivierung (2)
- T-Zellrezeptor (2)
- TAB08 (2)
- TCR (2)
- TGF-BETA (2)
- Therapie (2)
- Thymus (2)
- Transkriptionsfaktor (2)
- VLA-1 (2)
- Virology (2)
- Virulenz (2)
- Zelldifferenzierung (2)
- Zelltod (2)
- Zentralnervensystem (2)
- Zytoskelett (2)
- acid ceramidase inhibitor ceranib-2 (2)
- activation (2)
- alpaca (2)
- antigen presentation (2)
- avidity (2)
- azidothymidine (2)
- bcl-2 (2)
- binding protein (2)
- butyrophilin (2)
- butyrophilin 3 (2)
- costimulation (2)
- cytokine secretion (2)
- cytokines (2)
- cytoskeleton (2)
- cytotoxic T cells (2)
- domain (2)
- endothelial cells (2)
- expression (2)
- foamy viruses (2)
- gene regulation (2)
- genetics (2)
- glucocorticoid (2)
- glycoproteins (2)
- granzyme B (2)
- hemagglutinin (2)
- herpes simplex virus (2)
- hybrid vector (2)
- identification (2)
- immune suppression (2)
- immunologische Synapse (2)
- in-vivo (2)
- inflammation (2)
- lymph nodes (2)
- measels virus (2)
- mouse (2)
- multiple myeloma (2)
- neurodegeneration (2)
- neurovirulence (2)
- neutral sphingomyelinase-2 (2)
- oxidative stress (2)
- peripheral nervous system (2)
- plasma membrane (2)
- receptor (2)
- recombination (2)
- regulatory T-cells (2)
- regulatory t cells (2)
- resistance (2)
- retroviral vectors (2)
- retrovirus (2)
- sialic acid (2)
- signal transduction (2)
- signaltransduction (2)
- small interfering RNAs (2)
- sphingolipid (2)
- sphingosine kinase inhibitor SKI-II (2)
- therapy (2)
- toll-like receptors (2)
- translation (2)
- treatment (2)
- vaccination (2)
- viral load (2)
- γδ T cell (2)
- 1,2-benzisothiazolinone (1)
- 2',7'-dichlorofluorescin (1)
- 3-Dioxygenase (1)
- 3-dioxygenase (1)
- 3C-like protease (1)
- 3C-like-Protease (1)
- 3D Ko-kulture (1)
- 3D cell culture (1)
- 3D-Modell (1)
- 5`-UTR (1)
- 60-nucleotide duplication (1)
- ABCG2 (1)
- ACH-2 (1)
- ADP-Ribose-1"-Phosphatase (1)
- ADP-Ribose-1"-phosphatase (1)
- AKT-signaling (1)
- ASM (1)
- ASM-Inhibition (1)
- ATP-adenosine triphosphate (1)
- ATRA (1)
- Acetylcystein (1)
- Actinomycetes (1)
- Activation (1)
- Adaptation (1)
- Adaptive cell transfer (1)
- Adenovirus 5 (1)
- Adhesion (1)
- Aktin (1)
- Aktivierung (1)
- Allergie (1)
- Alloreaktion (1)
- Alloreaktivität (1)
- Allotransplantation (1)
- Alpha therapy (1)
- Alternative (1)
- Alternative Strategien (1)
- Alzheimer’s disease (1)
- Aminobisphosphonat (1)
- Aminobisphosphonate (1)
- Anpassung (1)
- Anti-Gehirn Autoantikörper (1)
- Antibody (1)
- Antibody responses (1)
- Antigen (1)
- Antigen CD25 (1)
- Antigen CD3 (1)
- Antigen CD9 (1)
- Antigen CD95 (1)
- Antigen presentation (1)
- Antigenerkennung (1)
- Antigenpräsentation (1)
- Antigentherapie (1)
- Antikörper gegen N-Protein (1)
- Antikörperantworten (1)
- Antikörperescape (1)
- Antioxidantien (1)
- Antisense (1)
- Arteriosklerose (1)
- Arthritis (1)
- Aspergillus (1)
- Aspergillus fumigatus (1)
- Assembly (1)
- Atemwegsinfektionen (1)
- Atemwegskrankheit (1)
- Atherosklerose (1)
- Auto-antibodies (1)
- Autoantigen (1)
- Autoimmune diseases (1)
- Autophagie (1)
- Autophagy (1)
- B Zelle (1)
- B cell differentiation (1)
- B-2 (1)
- B-Cells (1)
- B-Lympho (1)
- B-Lymphozyten-Rezeptor (1)
- B-Zell-Lymphom (1)
- B-Zelldifferenzierung (1)
- B-Zelle (1)
- B-cell signaling (1)
- B-cells (1)
- B-zells (1)
- BBC3 (1)
- BCG (1)
- BCR (1)
- BK virus (1)
- BK-Virus (1)
- BTN (1)
- BTN2 (1)
- BTN2A1 (1)
- BTN3A1 (1)
- BZR (1)
- Bakterien (1)
- Bauchspeicheldrüsenkrebs (1)
- Baumwollrattenmodell (1)
- Bcl-2-Proteinfamilie (1)
- Bim (1)
- Biologie (1)
- Biomarker (1)
- Biomarkers (1)
- Blockade (1)
- Blood Brain Barrier (1)
- Blut-Hirn-Schranke (1)
- Blutbildendes Gewebe (1)
- Blutstammzelle (1)
- Boccavirus (1)
- Bone marrow transplantantation (1)
- Borna Disease Virus (1)
- Bowen’s disease, periungual (1)
- Braak (1)
- Brugia Malayi (1)
- Bruton Tyrosine Kinase (1)
- Bryophyta (1)
- Budding (1)
- Bystander (1)
- C-terminal domain (1)
- C. albicans (1)
- CCS (1)
- CD 8 (1)
- CD25+CD4+ regulatory T cells (1)
- CD28 Superagonisten (1)
- CD28 costimulation (1)
- CD28 superagonists (1)
- CD28-SA (1)
- CD28-Superagonist (1)
- CD28-superagonist (1)
- CD38 (1)
- CD39 (1)
- CD4 T-Zellen (1)
- CD4 Zellen (1)
- CD4 cells (1)
- CD4 positiv T cells (1)
- CD4(+) T-cells (1)
- CD4(+)CD25(+) (1)
- CD4+ (1)
- CD4+ T cells (1)
- CD4+-CTL (1)
- CD4\(^{+}\) T cells (1)
- CD4\(^{+}\) T helper cells (1)
- CD57 (1)
- CD73 (1)
- CD8 (1)
- CD8 Effektorfunktionen (1)
- CD8 Gedächtnisreaktionen (1)
- CD8 T cell (1)
- CD8 T-Zell-Subpopulation (1)
- CD8 T-cell subpopulation (1)
- CD8+ T cells (1)
- CD8+ T-Zellen (1)
- CD8+ T-cells (1)
- CD8+-CTL (1)
- CD9 (1)
- CD95 (1)
- CDV (1)
- CLEC16A (1)
- CNS infection (1)
- COVID‐19 (1)
- COVID‐19 vaccination (1)
- CRAC (1)
- CRISPR/Cas-Methode (1)
- CSF (1)
- CVID (1)
- Ca2+ (1)
- Cancer (1)
- Candida (1)
- Capsidgen (1)
- Carcinogenese (1)
- Caspasen (1)
- Caspases (1)
- Cell migration (1)
- Cell signalling (1)
- Cerebrospinal fluid (CSF) (1)
- ChIP-seq (1)
- Chimäre <Biologie> (1)
- Chromatin (1)
- Citalopram (1)
- Collagenase (1)
- Common variable immunodeficiency (1)
- Coronaviral main protease (1)
- Coronavirale Hauptprotease (1)
- Costimulation (1)
- CpG-Inseln (1)
- Cytokine (1)
- Cytolyse (1)
- Cytolysis (1)
- Cytomegalovirus (1)
- Cytotoxicity (1)
- Cytotoxizität (1)
- DAPI staining (1)
- DAT (1)
- DC-SIGN (1)
- DC/T-Zell-Konjugate (1)
- DETC (1)
- DNA sequence (1)
- DNA transcription (1)
- DNA traps (1)
- DRAF1 (1)
- Deaminase (1)
- Dengue (1)
- Desaktivierung (1)
- Desaminase (1)
- Desaminierung (1)
- Desipramin (1)
- Diabetes Mellitus (1)
- Diabetes mellitus (1)
- Diabetes mellitus Typ 1 (1)
- Diagnostik (1)
- Disease genetics (1)
- Disease severity (1)
- Dolutegravir (1)
- Donor lymphocytes (1)
- Dopamin-Transporter (1)
- Dopamine transporter (1)
- Durchflusscytometrie (1)
- Dynabeads (1)
- EAAT (1)
- EIA (1)
- EMSA (1)
- ESCRT (1)
- ESCRT-System (1)
- EVER1 (1)
- EVER2 (1)
- Effektivität (1)
- Einfluss (1)
- Encephalomyelitis (1)
- Endogenes Ekzem (1)
- Endonucleasen (1)
- Endonuklease (1)
- Endothel (1)
- Endothelzelle (1)
- Endothelzellen (1)
- Enterovirus (1)
- Entzündung (1)
- Enzephalitis (1)
- Enzyme-linked immunosorbent assay (1)
- Epidemiology (1)
- Epithelzelle (1)
- Escherichia coli infections (1)
- Evaluation (1)
- Expression (1)
- Extracellular domain (1)
- Exzitotoxizität (1)
- Factor receptor (1)
- Falviviridae (1)
- Fanconi Anemia (1)
- Farnesyl Pyrophosphate Synthase (1)
- Farnesylpyrophosphatsynthase (FPPS) (1)
- Fibroblasten (1)
- Flt3L (1)
- Fluoreszenzaktivierter Zellsortierer (1)
- Flymphozyt (1)
- FoxP3 (1)
- Foxp3 (1)
- Friend Virus (1)
- Friend-Leukämievirus (1)
- Frühe Gene (1)
- Fusion (1)
- G glycoprotein (1)
- GBS (1)
- GDS (1)
- GFAP-Antikörper (1)
- GFAP-antibodies (1)
- GM-CSF (1)
- GRP78 (1)
- Gag protein (1)
- Gag-Proteine (1)
- GagPol fusion protein (1)
- Gedächtniszellen (1)
- Gehirn (1)
- Gelretentionsanalyse (1)
- Gen (1)
- Gen notch (1)
- Gene Targeting (1)
- Gene therapy (1)
- Genetik (1)
- Genotyp (1)
- Genotypverteilung (1)
- Genregulation (1)
- Gentheraphie (1)
- Gentheraphy (1)
- German people (1)
- Germany (1)
- Gliafaserprotein (1)
- Gliotoxin (1)
- Glucocorticoid receptor (1)
- Glucocorticosteroidrezeptor (1)
- Glukocorticioid (1)
- Glukokortikoid Rezeptor (1)
- Glutamat (1)
- Glycoproteins (1)
- Golgi (1)
- Graft versus Tumor (1)
- Graft-versus-leukemia (1)
- Granzym A (1)
- Granzym B (1)
- Granzyme B (1)
- Grippe (1)
- Growth Arrest (1)
- Guillain-Barré-Syndrom (1)
- H-Protein (1)
- H-protein (1)
- HAND (HIV assoziierte neurologische Störungen) (1)
- HBMEC (1)
- HCMV (1)
- HCoV-229E (1)
- HERV (1)
- HHV 6 (1)
- HIV Drug resistance (1)
- HIV South Africa (1)
- HIV dementia (1)
- HIV diagnosis and management (1)
- HIV infections (1)
- HIV neurocognitive impairment (1)
- HIV-1 Vif (1)
- HIV-1 subtype AG (1)
- HIV-1-infected patients (1)
- HIV-1; subtype C; proviral plasmid; viral replication; resistance assays; Vpu; CD317; CD4 (1)
- HIV-Demenz (1)
- HIV-Infection (1)
- HIV-Subtyp (1)
- HIV-Vektor (1)
- HIV-associated neurocognitive disorder (HAND) (1)
- HIV-associated neurological disorders (1)
- HIV-assoziierte neurokognitive Störung (1)
- HIV-assoziierte neurokognitive Störung (HAND) (1)
- HIV-assoziierte neurologische Erkrankungen (1)
- HIV-infection (1)
- HIV-vector (1)
- HLA-DR (1)
- HTLV-I (1)
- HUVEC (1)
- Hamburg (1)
- Hantavirus (1)
- Helicase (1)
- Helikase (1)
- Hepatitis B (1)
- Herpes simplex (1)
- Herpes-simplex-Virus (1)
- Herpesviren (1)
- Herpesvirus (1)
- Herpesviruses (1)
- High-Capacity Adenovirus (1)
- Hitzestress (1)
- Homing (1)
- Hsp90 (1)
- Human Parechovirus (1)
- Human foamy virus bel-l transactivator; Expression in insect cells (1)
- Humane Parechoviren (1)
- Humorale Immunität (1)
- Hypnales (1)
- Hämagglutinin (1)
- ICP27 (1)
- ICP4 (1)
- IE3 (1)
- IFN-g (1)
- IFN-gamma (1)
- IFNAR (1)
- IL-12 (1)
- IL-1RA (1)
- IL-2 (1)
- IL-4 (1)
- IL‐10 (1)
- IRAK2-Mutation N333D (1)
- IRAK2-defiziente Zellen (1)
- Ibrutinib (1)
- IgG (1)
- Immature B cell (1)
- Immunactivation (1)
- Immune activation (1)
- Immunesupression (1)
- Immunfluoreszenz (1)
- Immunität <Medizin> (1)
- Immunofluorescence Assay (1)
- Immunofluoreszenztest (1)
- Immunological synapse (1)
- Immunosuppression (1)
- Immunpathogenese (1)
- Immunsupression (1)
- Immuntherapie (1)
- IncRNA (1)
- Indolamin 2 (1)
- Infectious disease (1)
- Infektionen (1)
- Influenza (1)
- Inhibitor (1)
- Inhibitorproteine (1)
- Integrase (1)
- Integrase inhibitor (1)
- Integration (1)
- Integrin (1)
- Integrine (1)
- Interaction (1)
- Interaktionsrezeptor (1)
- Interferon <alpha-> (1)
- Interferon gamma (1)
- Interferonantagonism (1)
- Interferonantagonismus (1)
- Interferone (1)
- Interferonrezeptor (1)
- Interleukin 1-beta (1)
- Interleukin 10 (1)
- Interleukin-1 Rezeptorantagonist (1)
- Isopentenyl pyrophosphate (IPP) (1)
- Isopentenyl-pyrophosphat (IPP) (1)
- Isoprenoid Synthesis (1)
- Isoprenoide (1)
- Isoprenoidsynthese (1)
- Isotyp (1)
- JC-Virus (1)
- JCV (1)
- JNK (1)
- JURKAT-Zelle (1)
- Jurkat cells (1)
- KI-Polyomavirus (1)
- KRAS (1)
- Kardiomyopathie (1)
- Karibisches Meer (1)
- Keimzentrumsreaktion (1)
- Kerinokeratosis papulosa (1)
- Killerzelle (1)
- Kinasen (1)
- Kind (1)
- Klammeraffen (1)
- Knockout <Molekulargenetik> (1)
- Knockout Mice (1)
- Knockout Mäuse (1)
- Kohlenstoff (1)
- Kongress (1)
- Korezeptor (1)
- Krebs <Medizin> (1)
- LAD (1)
- LEW rat (1)
- LEW-Ratte (1)
- LFA-1 (1)
- LIF (1)
- LTR (1)
- Lamivudin (1)
- Langerhans cells (1)
- Leber und Dünndarmtransplantation (1)
- Lehrbuch (1)
- Lentiviren (1)
- Lentivirus (1)
- Ligand (1)
- Liquor (1)
- Lithiumtherapie (1)
- Liver and Small Bowel Transplantation (1)
- Lungenentzündung (1)
- Lymphocytes (1)
- Lymphom (1)
- Lymphomgenese (1)
- MALT (1)
- MALT-Typ Lymphom (1)
- MALT-type lymphoma (1)
- MAO-Hemme (1)
- MCMV (1)
- MEK/ERK-signaling (1)
- MHC (1)
- MHC I (1)
- MHC II (1)
- MHC Kl. I (1)
- MHC Klasse I (1)
- MHC Klasse II (1)
- MHC class I (1)
- MHC-Molekül (1)
- MHC-molecule (1)
- MIF (1)
- MIR-155 (1)
- MMTV (1)
- MPO (1)
- MRI (1)
- MS (1)
- MV receptor (1)
- MV transcription (1)
- Macrophage (1)
- Magnetaktivierter Zellsortierer (1)
- Major depression (1)
- Major splice donor (1)
- Malawi (1)
- Malignancies (1)
- Marginalzone (1)
- Masern Virus (1)
- Masern-Virus (1)
- Masernvirus Inhibitoren (1)
- Masernvirus-Infektion (1)
- Matrix Protein (1)
- Measles Virus (1)
- Measles Virus release (1)
- Measles virus (1)
- Measlesvirus (1)
- Mechanismus (1)
- Melanin (1)
- Membrane fusion (1)
- Membranfusion (1)
- Memory-B-Zellen (1)
- Mesocestoides corti (1)
- Metalloproteinase (1)
- Mikroglia (1)
- Milch (1)
- Mineralocorticoid receptor (1)
- Mineralokortikoid Rezeptor (1)
- Mitochondria (1)
- Molekulargenetik (1)
- Molekularpathologie (1)
- Monoclonal Antibodies (1)
- Monocytes and macrophages (1)
- Monozytendifferenzierung (1)
- Moose (1)
- Morbillivirus (1)
- Motoneuron (1)
- Multiple myeloma (1)
- Multiple sclerosis (1)
- Multiples Myelom (1)
- Multiplex-PCR (1)
- Mutation (1)
- Mutationen (1)
- Mutationsrate (1)
- Mycobacterium tuberculosis (1)
- Myelin Basic Protein Promoter (1)
- Myeloid-derived suppressor cells (1)
- Myeloma (1)
- N-CAM (1)
- N-Protein (1)
- N-oleoyl serinol (1)
- NF-kappaB (1)
- NFAT (1)
- NFATc1 (1)
- NFKB (1)
- NK cells (1)
- NK-Zellen (1)
- NKT (1)
- NKT Zellen (1)
- NKT cells (1)
- NMDA-Rezeptor (1)
- NOD Maus (1)
- NRF2 (1)
- Nail unit (1)
- Nanoröhre (1)
- Necrosis (1)
- Nectin4 (1)
- Neisseria meningitidis (1)
- Nekrose (1)
- Neuritis (1)
- Neurodegeneration (1)
- Neurografts (1)
- Neuromelanin (1)
- Neuroprotektion (1)
- Neurotoxizität (1)
- Neurovirulenz (1)
- Neuweltaffen (1)
- NfL (1)
- Nichtstrukturproteine (1)
- Norovirus (1)
- Notch1 (1)
- Nucleosidanaloga (1)
- Nucleotidanaloga (1)
- Nucleus (1)
- Nucleus accumbens (1)
- Nuklearfaktor Kappa B (1)
- OPN (1)
- Off-Label-Use (1)
- Osteopontin (1)
- Ovalbumin (1)
- Oxidativer Stress (1)
- PAR-CLIP (1)
- PARM (1)
- PBMC (1)
- PC61, anti-CD25-antibody (1)
- PC62, anti-CD25-Antiörper (1)
- PCI-32765 (1)
- PCR (1)
- PFV (1)
- PKB (1)
- PKB/Akt (1)
- PKCζ, (1)
- PML (1)
- PO (1)
- PRDI-BF1 (1)
- PTPN22 (1)
- Paramyxoviridae (1)
- Paramyxovirose (1)
- Parkinson Disease (1)
- Parkinsonism (1)
- Parkinsons Disease (1)
- Particleassembly (1)
- Partikelreifung (1)
- Partikelzusammenbau (1)
- Parvoviren (1)
- Pathway (1)
- Peak Caller (1)
- Penetration (1)
- Peptidtherapie (1)
- Perforin (1)
- Phage Display (1)
- Picornaviren (1)
- Picornavirus (1)
- Placebo (1)
- Plasmazellen (1)
- Plusstrangsynthese (1)
- Pneumoviruses (1)
- Po (1)
- Polyadenylation (1)
- Polymerase chain reaction (1)
- Polymerase-Protein (1)
- Polymerase-Proteine (1)
- Polymerasen (1)
- Polymorphismus (1)
- Polyomavirus (1)
- Polyomavirus JC (1)
- Polypurintrakt (1)
- PrP (1)
- Pra1 (1)
- Praeklampsie (1)
- Prednisolone (1)
- Primaten (1)
- Priming (1)
- Primärer Immundefekt (1)
- Primärresistenz (1)
- Prion protein (1)
- Prion-Protein (1)
- Prionen (1)
- Prionkrankheit (1)
- ProCort (1)
- Prodigy (1)
- Prognose (1)
- Progression zu AIDS (1)
- Promotor (1)
- Protease (1)
- Proteaseinhibitor (1)
- Prototyp-Foamyviren (1)
- Pseudovirion (1)
- Putamen (1)
- Pädiatrie (1)
- R0 (1)
- RAG1 (1)
- REDD1 (1)
- RNA Interferenz (1)
- RNA export (1)
- RNA structure (1)
- RNA-Export (1)
- RNA-Interferenz (1)
- RNA-Virus (1)
- RNAi (1)
- RNS-Bindung (1)
- RNS-Viren (1)
- RQQ domain (1)
- RSV-A ON1 (1)
- RT-qPCR (1)
- RT1B (1)
- RT1D (1)
- Reaktivierung (1)
- Real time quantitative PCR (1)
- Regeneration (1)
- Regluation (1)
- Regulation (1)
- Regulation of protease activity (1)
- Regulatorische T Zellen (1)
- Regulatorische T-Lymphozyt (1)
- Regulatory T cells (1)
- Regulatory-cells (1)
- RelB (1)
- Replikationskomplex (1)
- Resistances (1)
- Respiratory Infection (1)
- Respiratory infection (1)
- Respiratory tract infection (1)
- Resplex (1)
- Restriktionsenzym (1)
- Retroviraler Vektor (1)
- Retroviren-Infektion (1)
- Retrovirus (1)
- Retroviruses (1)
- Reverse Transkription (1)
- Rheumatoid arthritis (1)
- Ribavirin (1)
- S-Segment (1)
- SARS-CoV-2 brain disorders (1)
- SARS‐CoV‐2 (1)
- SARS‐CoV‐2 infection (1)
- SFVmac (1)
- SIV (1)
- SLAM CDW150 (1)
- SLAM-Code (1)
- SLAM-code (1)
- STEMI (1)
- STIM1 (1)
- STIM2 (1)
- Salmo trutta fario (1)
- Salzstress (1)
- Saure Sphingomyelinase (1)
- ScN2a Zellen (1)
- ScN2a cells (1)
- Schwangerschaft (1)
- Schwämme (1)
- Scrapie (1)
- Screening (1)
- Screeningtest (1)
- Seahorse XF (1)
- Sekundärmetabolit (1)
- Selegilin (1)
- Sequenzanalyse (1)
- Sequenzierung (1)
- Serotonin-Reuptake-Hemmer (1)
- Serotonin-Wiederaufnahmehemmer (1)
- Sertralin (1)
- Sialylsäure (1)
- Siglecs (1)
- Signalkaskaden (1)
- Signaltransduction (1)
- Skint1 (1)
- Slow-Virus-Infektion (1)
- Sphingolipidstoffwechsel (1)
- Sphingomyelinase (1)
- Sphingosin-1-Phosphat (1)
- Sphingosine-1-phosphate (1)
- Sphingosine-1-phosphats (1)
- Spumavirus (1)
- Stammbaum (1)
- Stammzelltransplantation (1)
- Stromelysin (1)
- Subakute Krankheit (1)
- Substratspezifität (1)
- Subtyp C (1)
- Superagonist (1)
- Superagonistic antibody (1)
- Superantigen (1)
- Suppression (1)
- Syncytin (1)
- Synthese (1)
- Säugling (1)
- Südafrika (1)
- T Cells (1)
- T Lymphozyt (1)
- T Zell Selektion (1)
- T cell acute lymphoblastic leukemia (1)
- T cell homeostasis (1)
- T cell migration (1)
- T cell receptor (TCR) (1)
- T cell selection (1)
- T cell silencing (1)
- T cell suppression (1)
- T helper 1 cells (1)
- T helper cell responses (1)
- T- Zelle (1)
- T-ALL (1)
- T-Helpercells (1)
- T-Lymphopenie (1)
- T-Zell Entwicklung (1)
- T-Zell Homöostase (1)
- T-Zell-Expansion (1)
- T-Zell-Lymphom (1)
- T-Zellaktivierung (1)
- T-Zellentwicklung (1)
- T-Zellmigration (1)
- T-Zellrezeptor (TZR) (1)
- T-cell (1)
- T-cell migration (1)
- T-cell receptor (1)
- T-cell-expansion (1)
- T-cells (1)
- T-lymphopeny (1)
- T-zellen (1)
- T/B-Zellinteraktion (1)
- T/B-cell-interaction (1)
- T1D (1)
- TAMs (1)
- TCF1 (1)
- TCF12 (1)
- TCR signaling cascade (1)
- TCRb (1)
- TGN1412 (1)
- TH2-Typ Cytokine (1)
- TH2-type cytokine (1)
- TITL (1)
- TLR2 (1)
- TLR4 (1)
- TNF (1)
- TNG1412 (1)
- TRDV2 (1)
- TRGV9 (1)
- Targeted Therapies (1)
- Taufliege (1)
- Tconv (1)
- Template Switching (1)
- Th1 (1)
- Th1 cells (1)
- Th2 (1)
- Thymozyten (1)
- Tierversuch (1)
- Tissue engineering (1)
- Tolerance (1)
- Toll-like Rezeptor 4 (1)
- Toll-ähnliche Rezeptoren (1)
- Toxoplasma gondii (1)
- Tr1 (1)
- Transcription (1)
- Transgen (1)
- Transgene (1)
- Transgene Tiere (1)
- Transkription (1)
- Transmission (1)
- Tubulin (1)
- Tumor Microenvironment (1)
- Tumor-necrosis-factor (1)
- Tumorwachstum (1)
- Typ 1 Diabetes (1)
- Ubiquitin- Proteasomen- Weg (1)
- Ubiquitin-Protein-Ligase (1)
- Ubiquitination (1)
- Ubiquitinierung (1)
- Uganda (1)
- Unreife B-Zelle (1)
- Untertyp (1)
- VH-Mutationsanalysen (1)
- VH-mutations (1)
- Vaccination (1)
- Vaccine (1)
- Vakzine (1)
- Variables Immundefektsyndrom (1)
- Varicella zoster (1)
- Vektor (1)
- Vereinfachung (1)
- Vg9Vd2 T Zellaktivierung (1)
- Vg9Vd2 T cell (1)
- Vgamma9Vdelta2 (1)
- Vietnam (1)
- Viktoriaseeregion (1)
- Viral infections (1)
- Virologische Synapse (1)
- Virostatikum (1)
- Virus-Transmission (1)
- Virus-Zell-Fusion (1)
- Virus-like particles (1)
- Virus-ähnliche Partikel (1)
- Virusanzucht (1)
- Virusinfection (1)
- Virusinfektionen (1)
- Virusnachweis (1)
- Viruzid (1)
- Vγ9Vδ2 (1)
- Vγ9Vδ2 T cell (1)
- WASp (1)
- WEHI 231 (1)
- WU-Polyomavirus (1)
- Wachstumsstopp (1)
- Waxy papulosis of childhood (1)
- Wiskott-Aldrich syndrome (1)
- Wue-1 (1)
- ZAP-70 (1)
- Zell Migration (1)
- Zell-Zell-Fusion (1)
- Zelladhesion (1)
- Zelladhäsion (1)
- Zellfusion (1)
- Zellkonjugation (1)
- Zellkultur (1)
- Zelloberfläche (1)
- Zellrezeptor (1)
- Zellskelett (1)
- Zelluläre Immunität (1)
- Zidovudin (1)
- Zytokine (1)
- Zytolyse (1)
- Zytoskelettreorganisation (1)
- acetylsalicylic acid (1)
- acid ceramidase (1)
- acquisition of host regulators (1)
- actin (1)
- actins (1)
- acute Graft versus Host Disease (1)
- acute graft-versus-host disease (1)
- acute heart failure (1)
- acute kidney injury (1)
- adaptive immune response (1)
- adenosine (1)
- adhesion (1)
- admission screening (1)
- adoptive transfer (1)
- adult (1)
- age groups (1)
- aging (1)
- alloreaction (1)
- alloreactivity (1)
- alpha-globin (1)
- alternative splicing (1)
- alternative strategies (1)
- alveoar echinococcosis (1)
- amplicon sequencing (1)
- anemia (1)
- anergy (1)
- angiogenesis (1)
- animal models (1)
- anthocyanin (1)
- anti- apoptotic Bcl-2 family member A1 (1)
- anti- apoptotisches Bcl-2 Familienmitglied A1 (1)
- anti-GFAP (1)
- anti-brain autoantibodies (1)
- anti-depressant drug (1)
- anti-hiv agents (1)
- anti-myocardial (1)
- anti-protease (1)
- anti-retroviral agents (1)
- antiapoptotic Bcl-2 family member A1 (1)
- antiapoptotisches Bcl-2 Familienmitglied A1 (1)
- antibodies against n-protein (1)
- antibody (1)
- antibodyescape (1)
- antidepressants (1)
- antigen therapy (1)
- antigen-B (1)
- antigen-specific (1)
- antigenic recall (1)
- antimicrobial resistance (1)
- antioxidants (1)
- antiretrovirals (1)
- antiviral activity (1)
- antiviral treatment (1)
- antivirale Substanzen (1)
- anti‐SARS‐CoV‐2‐spike IgG (1)
- aorta (1)
- aorta ring (1)
- arteriosclerosis (1)
- arthritis (1)
- aspirin (1)
- astaxanthin (1)
- atherosclerosis (1)
- atopische Deramtitis (1)
- attachment glycoprotein (1)
- autoantibodies (1)
- autoantibody (1)
- avidity testing (1)
- azapeptide nitriles (1)
- azido-ceramides (1)
- bacteria (1)
- bacterial expression (1)
- bacterial pathogens (1)
- bakterielle Expression (1)
- bilberry (1)
- binding analysis (1)
- biochemical assays (1)
- bioinformatic (1)
- black currant (1)
- black trout syndrome (1)
- blocking opsonization (1)
- blocking phagocytosis (1)
- bone marrow (1)
- brain (1)
- brain bank (1)
- brain pathology (1)
- brain stem (1)
- branch point (1)
- brown trout (1)
- budding (1)
- butyrophilin 2A1 (1)
- butyrophilins (1)
- cDC2 subset (1)
- calcium (1)
- calnexin (1)
- canine (1)
- canine distemper virus (1)
- capsid gene (1)
- cardiac magnetic resonance imaging (1)
- cardiorespiratory centre (1)
- caveolin-1 (Cav-1) (1)
- cd28 superagonists (1)
- cell adhesion (1)
- cell cycle and cell division (1)
- cell death (1)
- cell differentiation (1)
- cell line specificity pyridyl indole carboxylates (1)
- cell membrane (1)
- cell membrane model (1)
- cell migration (1)
- cell-cell-Fusion (1)
- cell-cycle dependence (1)
- cells (1)
- cellular immunity (1)
- cellular receptor (1)
- cellular stress responses (1)
- central-nervous-system (1)
- ceramidase (1)
- cerebrospinal fluid (1)
- channel (1)
- characterization and analytical techniques (1)
- chemotaxis (1)
- chikungunya virus (1)
- child (1)
- children (1)
- cholera (1)
- cholesteryl ester (1)
- chondrogenesis (1)
- chromatin (1)
- chronic immune activation (1)
- chronic rhinosinusitis (1)
- chronical-infected cells (1)
- chronisch-infizierte Zellen (1)
- circulation patterns (1)
- cis-acting sequences (1)
- co-evolution (1)
- co-stimulation, (1)
- coevolution (1)
- cognitive dysfunction (1)
- collagenase (1)
- complement (1)
- complement factor H (1)
- complex (1)
- complex retrovirus (1)
- conversion (1)
- coreceptor (1)
- coronavirus (1)
- cotton rat (1)
- criteria (1)
- critically ill (1)
- cross-linking (1)
- cryptic peptides (1)
- cytokine release (1)
- cytokine release syndrome (1)
- cytokine responses (1)
- cytosceleton (1)
- cytoskeletal reorganisation (1)
- decay (1)
- defective ribosomal products (1)
- degradation (1)
- demyelination (1)
- dendritische Zelle (1)
- dendritische Zellen (1)
- dengue virus (1)
- dentritische Zellen (1)
- depression (1)
- diacylglycerol (1)
- diagnostic (1)
- diet (1)
- differential diagnosis (1)
- differentiation (1)
- direct stimulation (1)
- direct-acting antivirals (1)
- direkte Stimulation (1)
- disease severity (1)
- distribution (1)
- diversity (1)
- dmrt1 (1)
- dna-binding protein (1)
- dogs (1)
- dopamine (1)
- drosophila melanogster (1)
- drug adherence (1)
- drug discovery (1)
- drug interactions (1)
- embryo (1)
- endonuclease (1)
- endothelial cell infection (1)
- enhance viral transcription (1)
- env leader protein (1)
- enzyme-linked immunoassays (1)
- enzymes (1)
- epicutaneous (1)
- epidemiology (1)
- epitope mapping (1)
- epitope specificity (1)
- epstein-barr virus (1)
- excitotoxicity (1)
- exclusion criteria (1)
- excretory-secretory (1)
- factor H (1)
- fibroblasts (1)
- fluorescence-activated cell sorting (1)
- fluoxetine (1)
- foamy (1)
- foamy retrovirus (1)
- foamyviruses (1)
- fungal infection (1)
- fusion (1)
- fusion and fission (1)
- gamma-interferon (1)
- gammadelta T Zelle (1)
- gammadelta T cel l (1)
- gd T Zellen (1)
- gd T cells (1)
- gemischt (1)
- gemischte Lymphozytenreaktion (1)
- gene delivery (1)
- gene-expression (1)
- genetic conservation (1)
- genetic interference (1)
- genetic variability (1)
- genotype (1)
- germinal centre (1)
- glial damage (1)
- glial fibrillary acidic protein (1)
- glutamate (1)
- glycolipids (1)
- glycosphingolipids (1)
- granulosus (1)
- granzyme A (1)
- group B genotype (1)
- group-A (1)
- guidelines (1)
- hACE2 (1)
- hantavirus (1)
- healthcare workers (1)
- heart (1)
- heart failure (1)
- helicase (1)
- helminth infection (1)
- helminths (1)
- hematological disorders (1)
- hematopoietic stem cell (1)
- hepadnaviruses (1)
- heroine (1)
- heterolog (1)
- heterologous (1)
- high-capacity adenovirus (1)
- highly-active antiretroviral therapy (1)
- histones (1)
- homeostasis (1)
- homing (1)
- host shutoff (1)
- host-pathogen interactions (1)
- human bocavirus (1)
- human immunodeficiency virus (1)
- human peripheral blood (1)
- humans (1)
- hydatid disease (1)
- immediate early genes (1)
- immune cells (1)
- immune control (1)
- immune escape (1)
- immune modulation (1)
- immune neuromelanin (1)
- immune pathogenesis (1)
- immune response (1)
- immune therapy (1)
- immunisation (1)
- immunization (1)
- immuno suppression (1)
- immunoglobulin superfamily (1)
- immunologic tolerance (1)
- immunological synapse (1)
- immunomodulation (1)
- immunomodulatory (1)
- immunoprecipitation (1)
- immunsuppression (1)
- immunsystem (1)
- immuntherapy (1)
- improves survival (1)
- in vivo (1)
- indinavir (1)
- indoleamine 2 (1)
- inducible deletion (1)
- inducible nitric oxide synthase (1)
- induzierte regulatorische T-Zellen (1)
- infarction size (1)
- infected mice (1)
- infected-cell protein (1)
- infection control (1)
- infection spread (1)
- infectivity assays (1)
- influenza (1)
- influenza A virus (1)
- influenza virus (1)
- inhibitorisch (1)
- inhibitorische Rezeptoren (1)
- inhibitory (1)
- inhibitory receptors (1)
- injecting drug users (1)
- innate immune response (1)
- innate lymphoid cells (1)
- integration (1)
- integration site selection (1)
- interferon signaling (1)
- interferon γ (1)
- interleukin 1 receptor antagonist (1)
- interleukins (1)
- intraarticular (1)
- intraartikulär (1)
- invariant NKT cells (1)
- invariante NKT Zellen (1)
- isotype (1)
- kidneys (1)
- kinases (1)
- klinische Studie (1)
- komplexer Retrovirus (1)
- konventionelle CD4 T Zellen (1)
- large gene lists (1)
- larvae (1)
- latency (1)
- lethality rate (1)
- leukemia (1)
- lipids (1)
- liposome (1)
- lithium (1)
- long terminal repeat (1)
- longevity (1)
- luciferase assay (1)
- lymphocyte activation (1)
- lymphomagenesis (1)
- lymphomas (1)
- lyso-phospholipids (1)
- lytic infection (1)
- mRNA (1)
- mTORC1 (1)
- magnetic properties and materials (1)
- major depression (1)
- major histocompatibility complex (1)
- management (1)
- marginal zone (1)
- marine sponge (1)
- matrix protein (1)
- measles virus infection (1)
- mechanism (1)
- mediated suppression (1)
- medical (1)
- medical research (1)
- mematine (1)
- memory B cells (1)
- memory b cell (1)
- memory cells (1)
- meningococcal disease (1)
- mesenchymal stem cell (1)
- messenger RNA (1)
- metacestode vesicles (1)
- metalloproteinase (1)
- mevalonate pathway (1)
- miR-30 (1)
- miRNA (1)
- miRNA processing (1)
- miRNA target (1)
- miRNS (1)
- mice (1)
- microRNA (1)
- microbial mutation (1)
- microbiology (1)
- microglia (1)
- migration (1)
- milk (1)
- mitochondria (1)
- mixed (1)
- modulation of immune response (1)
- molecular biology (1)
- molecular characterization (1)
- molecular cloning (1)
- molecular epidemiology (1)
- molekulare Epidemiologie (1)
- monoclonal antibodies (1)
- monocyte (1)
- monocyte differentiation (1)
- moonlighting (1)
- morbillivirus (1)
- morbilliviruses (1)
- morphine (1)
- mortality (1)
- mothers (1)
- motif discovery (1)
- motifs (1)
- motility (1)
- mouse models (1)
- movement disorders (1)
- mukosale Immunantwort (1)
- multi-drug resistance (1)
- multihit targeting (1)
- multiple Sklerose (1)
- murine cytomegalovirus (MCMV) (1)
- murine model (1)
- mutant mice (1)
- mutation databases (1)
- mutationrate (1)
- mutations (1)
- mycobacteria (1)
- myelin (1)
- myeloid-derived suppressor cell (MDSC) (1)
- myeloid-derived suppressor cells (MDSCs) (1)
- myocardial infarction (1)
- n-protein (1)
- naloxone (1)
- nanobiocomposites (1)
- nanoparticles (1)
- nasal polyps (1)
- natürliche regulatorische T-Zellen (1)
- necrosis-factor-alpha (1)
- nervous-system (1)
- neurofilament light chain (1)
- neurografts (1)
- neuroinflammation (1)
- neuroinvasion (1)
- neurological symptoms/disorders (1)
- neutral sphingomyelinase (1)
- neutral sphingomyelinase 2 (1)
- new respiratory viruses (1)
- new world monkeys (1)
- next generation sequencing (1)
- nine-banded armadillo (1)
- non-canonical translation (1)
- non-nucleoside reverse transcriptase inhibitors (1)
- nucleosides (1)
- oligomers (1)
- opioids (1)
- ortholog (1)
- orthoreovirus (1)
- outpatients (1)
- ovarian cancer (1)
- oxidative phosphorylation (1)
- pH-regulated antigen 1 (Pra1) (1)
- pancreatic cancer (1)
- parainfluenza virus (1)
- parasitic diseases (1)
- parasitology (1)
- particle maturation (1)
- pathogenesis (1)
- pediatric infections (1)
- pediatrics (1)
- pellet culture (1)
- peptidomimetics (1)
- perforin (1)
- peripheral tolerance (1)
- persistierende Infektion (1)
- perspectives (1)
- phagocytosis (1)
- phosphoantigens (1)
- phylogenetische Analyse (1)
- piscine orthoreovirus (1)
- placental mammals (1)
- plasma cells (1)
- plasminogen (1)
- plus strand synthesis (1)
- pneumona virus (1)
- pol messenger-rna (1)
- polarization (1)
- poly(A) site usage (1)
- polyadenylation (1)
- polymicrobial sepsis (1)
- polymorphism (1)
- polyomavirus (1)
- polyomaviruses (1)
- population coverage (1)
- positive Selektion (1)
- positive selection (1)
- positive thymic selection (1)
- positive thymische Selektion (1)
- postmortem studies (1)
- pre-messenger RNA (1)
- precision-cut lung slices (1)
- prediction (1)
- preeclampsia (1)
- pregnancy (1)
- prevention (1)
- primary cells (1)
- primary infection (1)
- prion (1)
- prions (1)
- progression to AIDS (1)
- proliferation (1)
- proliferative darkening syndrome (1)
- promoter (1)
- promoter-proximal pausing (1)
- protease inhibitors (1)
- protein regulation and expression (1)
- protein sequencing (1)
- proteomic analysis (1)
- prototyp foamyviruses (1)
- pseudovirion (1)
- public health medicine (1)
- purine-rich element (1)
- purine-rich region (1)
- qualitative PCR (1)
- quantitative real-time PCR (1)
- randomized controlled clinical trial (1)
- randomized controlled-trial (1)
- reactivation (1)
- real-time-PCR (1)
- recognition (1)
- recombinant proteins (1)
- regulation (1)
- regulatorische T Zelle (1)
- regulatory T cell (1)
- regulatory T cells (Treg) (1)
- regulatory protein ICP27 (1)
- remdesivir (1)
- replication complex (1)
- replikative senescence (1)
- respiratory syncytial virus (1)
- respiratory tract (1)
- restriction factors (1)
- retardeted virus (1)
- retargeted measles virus (1)
- retinal pigment epithelium (1)
- retinales Pigmentepithel (1)
- retroviral gene transfer (1)
- retroviral infection (1)
- retroviral proteins (1)
- retroviral vector (1)
- retrovirale Integrationsmuster (1)
- retrovirale Vektoren (1)
- retroviraler Gentransfer (1)
- retroviraler Vektor (1)
- retroviruses (1)
- reverse Genetik (1)
- reverse Transkription (1)
- reverse genetics (1)
- reverse transcriptase inhibitors (1)
- reverse transcriptase-polymerase chain reaction (1)
- reverse transcription (1)
- reverse-transcriptase (1)
- reverse-transcriptase inhibitors (1)
- rheumatoid arthritis (1)
- ribavirin (1)
- ribonuclease H (1)
- routine clinical-practice (1)
- s-segment (1)
- salicylic acid (1)
- saure Sphingomyelinase (1)
- scrapie (1)
- self-reactivity (1)
- sepsis (1)
- sequence (1)
- sequence databases (1)
- seroprevalence (1)
- serum (1)
- sex-determining gene (1)
- shock (1)
- siRNA (1)
- signalling cascades (1)
- simian foamy viruses (1)
- simplification (1)
- spezifisch (1)
- sphingomonads (1)
- sphingosine 1-phosphate (1)
- sphingosine kinase (1)
- spider monkey (1)
- spleen (1)
- splice regulation (1)
- splicing (1)
- splicing inhibition (1)
- spread (1)
- spumavirus (1)
- steady state (1)
- steady-state dendritic cells (1)
- sterol pathway (1)
- strains (1)
- stress (1)
- stress resistance (1)
- stroke (1)
- stromelysin (1)
- subacute sclerosing-panencephalitis (1)
- subgroup-B (1)
- substrate specifity (1)
- subviral particle release (1)
- superagonist (1)
- superagonistische Funktion (1)
- surface transport (1)
- surfactants (1)
- surveillance (1)
- t cell development (1)
- t cells (1)
- t(11;18)(q21;q21) (1)
- t-cell (1)
- t-cells (1)
- tanzania (1)
- template switching (1)
- terminal differentiation (1)
- terminal gag domain (1)
- terminale Differenzierung (1)
- testing strategy (1)
- th1 (1)
- th2 (1)
- the microtubule-organizing center (1)
- thermal stresses (1)
- thymocyte (1)
- tissue (1)
- tolerogenic dendritic cells (1)
- toxins (1)
- transcription (1)
- transcription factors (1)
- transcriptional profiling (1)
- transcriptional termination (1)
- transcriptional transactivator (1)
- transcriptomics (1)
- transcutaneous (1)
- transduction (1)
- transient regulatory T-cell targeting (1)
- transkriptioneller Transaktivator (1)
- transmembrane protein (1)
- tubulin (1)
- tumor (1)
- tumor associated macrophages (1)
- type 1 (1)
- type 1 ICP27 (1)
- type I interferon (1)
- tyrosine (1)
- ubiquitin- proteasome- pathway (1)
- ultraviolet radiation (1)
- unwindase (1)
- vaccination and immunization (1)
- vaccine (1)
- vaccinia virus (1)
- vector (1)
- vero cells (1)
- vesicles (1)
- viral entry (1)
- viral epidemiology (1)
- viral infection (1)
- viral miRNAs (1)
- viral microRNAs (1)
- viral pathology (1)
- viral replication (1)
- viral shedding (1)
- virale Penetration (1)
- virale Proteine (1)
- virological synapse (1)
- virulence (1)
- virus budding (1)
- virus entry (1)
- virus host interaction (1)
- virus reactivation (1)
- virus replication (1)
- virus transmission (1)
- virus vectors (1)
- virus-cell-Fusion (1)
- virus-induced encephalitis (1)
- viruses (1)
- vitamin-D-receptor (1)
- vivo (1)
- wild-type (1)
- world health organization (1)
- xxx (1)
- zelluläre Immunität (1)
- zytotoxisch (1)
- zytotoxische T-Zellen (1)
- α-synuclein-specific T cells (1)
- γδ T cells (1)
- γδ TCR (1)
Institute
- Institut für Virologie und Immunbiologie (417) (remove)
Sonstige beteiligte Institutionen
- Datenintegrationszentrum Würzburg (DIZ) (1)
- Hans-Knöll-Institut Jena (1)
- Interdisziplinäre Biomaterial- und Datenbank Würzburg (ibdw) (1)
- Interdisziplinäres Zentrum für Klinische Forschung (ZIKF), Würzburg (1)
- Joslin Diabetes Center (Harvard Medical School) (1)
- Joslin Diabetes Center, Harvard Medical School (1)
- Roche Diagnostics GmbH Penzberg (1)
- University of Stellenbosch, Division of Medical Virology (1)
- Universität Jena (1)
EU-Project number / Contract (GA) number
- 721016 (2)
- 249177 (1)
- 825575 (1)
- 955974 (1)
- CoG 721016–HERPES (1)
- ERC-2016-CoG 721016-HERPES (1)
Das Masernvirus (MV) kann in Erkrankten eine schwere, langanhaltende Immunsuppression verursachen, wodurch Infektionen mit opportunistischen Pathogenen begünstigt werden. Diese basiert auf einer Paralyse der hämatopoetischen Zellen, welche das Virus durch Kontakt eines viralen Glykoproteinkomplexes zu einem unbekannten RezeptorX auf der Zell- Oberfläche induzieren kann. Kerncharakterisitika hiervon sind unter anderem die Herabregulation der Akt-Kinase-Phosphorylierung, die Inhibition der zellulären Proliferation und die Aktivierung der neutralen Sphingomyelinase 2 (NSM2).
In einem kinetischen Phosphoproteom konnten zwei potentielle Interaktionsrezeptoren des MV identifiziert werden: CD43 und P2X3. Das hochglykosylierte Oberflächenmolekül CD43 ist auf hämatopoetischen Zellen ubiquitär exprimiert und reguliert in T-Zellen deren Überleben, Proliferation, Aktivierung, Migration und Adhäsion. P2X3 wird in hämatopoetischen Zellen nur in geringem Maße exprimiert. Seine funktionelle Bedeutung ist in diesem Kompartiment nicht bekannt. Beide Kandidaten wurden mittels CRISPR/Cas9 Verfahren einzeln oder kombiniert aus Jurkat-T-Zellen ablatiert, welche nachfolgend nach MV-Kontakt hinsichtlich der oben erwähnten MV-modulierten Parameter getestet wurden. Zusätzlich wurden iso- und allosterische P2X3-Inhibitoren an primären und Jurkat-T-Zellen verwendet, um dessen Rolle in Ca2+-Mobilisierung und Proliferation nach T-Zell-Rezeptor Co-Stimulation zu analysieren.
Die genetische Depletion beider Rezeptor-Kandidaten verringerte die Effekte des MV auf alle getesteten Parameter signifikant, was darauf hindeutet, dass beide Proteine entscheidend an der T-Zell-Suppression beteiligt sind. Während die isosterische Inhibition von P2X3 keinen Effekt hatte, wurde die Proliferation primärer T-Zellen durch dessen allosterische Inhibition vor Co-Stimulation fast verdoppelt und die Effizienz der Ca2+-Mobilisierung in Jurkat- und primären T-Zellen signifikant erhöht. In P2X3-depletierten Jurkat-Zellen hingegen war die Ca2+-Mobilisierung nach Stimulation signifikant geringer als in WT-Zellen.
In dieser Arbeit konnten zwei wichtige Mediatoren der MV induzierten T-Zell-Suppression identifiziert werden. Vor allem P2X3, dessen Expression, Regulation und funktionelle Bedeutung im hämatopoetischen Kompartiment noch nicht erforscht wurde, könnte ein vielversprechender Kandidat für eine antivirale Therapie darstellen, da ein klinisch getesteter P2X3-Inhibitor bereits verfügbar ist.
N-Glykosylierungen spielen beim Env-Gen eine wichtige Rolle. Sie dienen nicht nur als „Escape-Phänomen“ zur Verhinderung einer Elimination des Virus durch neutralisierende Antikörper. Es hat sich gezeigt, dass bestimmte Menschen sich mit HIV infizieren können, aber es zu keinem Zeitpunkt zu AIDS-typischen Symptomen kommt, ohne die Einnahme antiretroviraler Therapie (ART). Solche Menschen werden als Elite Controller bezeichnet. Ihr Organismus kann selbst die Viruslast in sehr geringen Grenzen halten (< 50 Kopien/ml). Ziel dieser Arbeit ist es, den Einfluss von N-Glykosylierungen in der Entstehung von Elite Controller zu untersuchen und prozentuell eine Tendenz zu schaffen, inwieweit die Glykosylierungsdichte des Env-Proteins entscheidend ist. Es konnte gezeigt werden, dass eine immunologische Kontrolle auch auf der B-Zellebene stattfinden kann. Als Hinweis dient die geringe Glykosylierungsdichte im Bereich CD4bs und MPER, die indirekt über MHC Klasse II zu einer erhöhten Produktion von Antikörpern führen kann. Bisher wurde bei Elite Controller die T-Zellebene als mögliche immunologische Kontrolle beschrieben, jedoch gibt diese Arbeit hinweise, dass auch eine immunologische Kontrolle mittels Antikörper möglich ist. Die glykosylierten Zielepitope können eine große Hilfe sein für das Aussehen eines späteren Impfstoffs.
Im Jahr 2015 wurde Plasmaproben von 161 HIV-positive Menschen auf HIV-Drug-Resistance untersucht. Die Patienten waren therapienaiv und wurde am Lighthouse-Hospital in Lilongwe, die Hauptstadt Malawis behandelt. Es zeigte sich eine HIVDR von insgesamt 17% welche aus mehreren Gesichtspunkte dargestellt worden sind, um zu zeigen ob 20105 in Malawi eingesetzte first-line Therapieregime eine gute Wirksamkeit zeigte.
MDSCs are suppressive immune cells with a high relevance in various pathologies including cancer, autoimmunity, and chronic infections. Surface marker expression of MDSCs resembles monocytes and neutrophils which have immunostimulatory functions instead of suppressing T cells. Therefore, finding specific surface markers for MDSCs is important for MDSC research and therapeutic MDSC manipulation. In this study, we analyzed if the integrin VLA-1 has the potential as a novel MDSC marker. VLA-1 was expressed by M-MDSCs but not by G-MDSCs as well as by Teff cells. VLA-1 deficiency did not impact iNOS expression, the distribution of M-MDSC and G-MDSC subsets, and the suppressive capacity of MDSCs towards naïve and Teff cells in vitro. In mice, VLA-1 had no effect on the homing capability of MDSCs to the spleen, which is a major reservoir for MDSCs. Since the splenic red pulp contains collagen IV and VLA-1 binds collagen IV with a high affinity, we found MDSCs and Teff cells in this area as expected. We showed that T cell suppression in the spleen, indicated by reduced T cell recovery and proliferation as well as increased apoptosis and cell death, partially depended on VLA-1 expression by the MDSCs. In a mouse model of multiple sclerosis, MDSC injection prior to disease onset led to a decrease of the disease score, and this effect was significantly reduced when MDSCs were VLA-1 deficient. The expression of Sema7A by Teff cells, a ligand for VLA-1 which is implicated in negative T cell regulation, resulted in a slightly stronger Teff cell suppression by MDSCs compared to Sema7A deficient T cells. Live cell imaging and intravital 2-photon microscopy showed that the interaction time of MDSCs and Teff cells was shorter when MDSCs lacked VLA 1 expression, however VLA-1 expression had no impact on MDSC mobility. Therefore, the VLA-1-dependent interaction of MDSC and Teff cells on collagen IV in the splenic red pulp is implicated MDSC-mediated Teff cell suppression.
Recently, we have shown that C6-ceramides efficiently suppress viral replication by trapping the virus in lysosomes. Here, we use antiviral assays to evaluate a synthetic ceramide derivative α-NH2-ω-N3-C6-ceramide (AKS461) and to confirm the biological activity of C6-ceramides inhibiting SARS-CoV-2. Click-labeling with a fluorophore demonstrated that AKS461 accumulates in lysosomes. Previously, it has been shown that suppression of SARS-CoV-2 replication can be cell-type specific. Thus, AKS461 inhibited SARS-CoV-2 replication in Huh-7, Vero, and Calu-3 cells up to 2.5 orders of magnitude. The results were confirmed by CoronaFISH, indicating that AKS461 acts comparable to the unmodified C6-ceramide. Thus, AKS461 serves as a tool to study ceramide-associated cellular and viral pathways, such as SARS-CoV-2 infections, and it helped to identify lysosomes as the central organelle of C6-ceramides to inhibit viral replication.
Recently, we have described novel pyridyl indole esters and peptidomimetics as potent inhibitors of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) main protease. Here, we analysed the impact of these compounds on viral replication. It has been shown that some antivirals against SARS-CoV-2 act in a cell line-specific way. Thus, the compounds were tested in Vero, Huh-7, and Calu-3 cells. We showed that the protease inhibitors at 30 µM suppress viral replication by up to 5 orders of magnitude in Huh-7 cells, while in Calu-3 cells, suppression by 2 orders of magnitude was achieved. Three pyridin-3-yl indole-carboxylates inhibited viral replication in all cell lines, indicating that they might repress viral replication in human tissue as well. Thus, we investigated three compounds in human precision-cut lung slices and observed donor-dependent antiviral activity in this patient-near system. Our results provide evidence that even direct-acting antivirals may act in a cell line-specific manner.
Zusammenfassung
Hintergrund: Das saure Gliafaserprotein (GFAP) kommt im ZNS vor allem in Astrozyten vor und spielt eine Rolle bei der Astrozytose, die wiederum ist ein pathogenetisches Merkmal von HIV-assoziierten neurologischen Erkrankungen (HAND). In dieser Arbeit wird das Vorkommen von GFAP-Autoantikörpern bei PLWH und deren Bedeutung bei der Entstehung von HAND untersucht. Außerdem wird eruiert, ob GFAP-Autoantikörper als Marker eines neurokognitiven Defizites bei HAND in Frage kommen.
Methoden: Homogenisiert Gewebeschnitte von verschiedenen Gehirnareale wurden mittels SDS-Gelelektrophorese und Western Blot auf Membranen übertragen. Diese Membranen wurden mit Blutproben aus der HAND-1 Studie inkubiert. Der Nachweis von GFAP-Antikörpern erfolgte indirekt mittels eines IgG-Antikörpers. Die Anti-GFAP Signalintensitäten wurden semiquantitativ ausgewertet und mit den Daten der neurokognitiven Test der HAND-1 Studie korreliert.
Egebnisse: Die GFAP-Autoantikörper Signalintensität unterscheidet sich je nach Gehirnareal (p < 0,0001). Insbesondere die DM-Signale sind signifikant stärker als die der anderen Areale (p < 0,01). Es lässt sich insgesamt kein signifikanter Unterschied in der Signalstärke zwischen Menschen mit HIV und Kontrollen feststellen (p = 0,1742). Bei der HIV-Gruppe zeigt das Gesamtergebnis des MMS einen signifikanten, negativen und starken Zusammenhang mit der GFAP- Antikörpersignalintensität der Areale DM (p = 0,004), ST (p = 0,011), MC (p = 0,007) und FC (p = 0,002). Es konnten keine signifikanten Korrelationen zwischen den CD4-Zellzahlen und den Anti-GFAP Signalintensitäten festgestellt werden. Bei der Kontrollgruppe fanden sich lediglich vereinzelt signifikante Korrelationen.
Diskussion: Diese Promotion ist die bis dato erste Veröffentlichung, in der GFAP-Autoantikörper bei Menschen mit HIV gemessen wurden. Dass kein Unterschied im Vorkommen von GFAP-Ak bei PLWH und der Kontrollgruppe gefunden wurde, könnte an der geringen Teilnehmendenzahl oder am Mangel von Teilnehmenden mit HAD liegen. Andererseits könnte es auch dafür sprechen, dass anti-GFAP nicht obligat pathogen ist, sondern erst nach Übertritt über die Blut-Hirn-Schranke pathologische Folgen hat. Für diese Hypothese spricht die Erkenntnis, dass eine höhere Menge von GFAP-Ak mit einem schlechteren Abschneiden bei neurokognitiven Tests korreliert. Demnach könnten sich GFAP-Autoantikörper als diagnostische und möglicherweise prognostische Marker eines neurokognitiven Defizites bei HAND eignen.
Gene expression in eukaryotic cells is regulated by the combinatorial action of numerous gene-regulatory factors, among which microRNAs (miRNAs) play a fundamental role at the post-transcriptional level. miRNAs are single-stranded, small non-coding RNA molecules that emerge in a cascade-like fashion via the generation of primary and precursor miRNAs. Mature miRNAs become functional when incorporated into the RNA induced silencing complex (RISC). miRNAs guide RISCs to target mRNAs in a sequence-specific fashion. To this end, base-pairs are usually formed between the miRNA seed region, spanning nucleotide positions 2 to 8 (from the 5' end) and the 3'UTR of the target mRNA. Once miRNA-mRNA interaction is established, RISC represses translation and occasionally induces direct or indirect target mRNA degradation. Interestingly, miRNAs are expressed not only in every multicellular organism but are also encoded by several viruses, predominately by herpesviruses. By controlling both, cellular as well as viral mRNA transcripts, virus-encoded miRNAs confer many beneficial effects on viral growth and persistence. Murine cytomegalovirus (MCMV) is a ß-herpesvirus and so far, 29 mature MCMV-encoded miRNAs have been identified during lytic infection. Computational analysis of previously conducted photoactivated ribonucleotide-enhanced individual nucleotide resolution crosslinking immunoprecipitation (PAR-iCLIP) experiments identified a read cluster within the 3' untranslated region (3'UTR) of the immediate early 3 (IE3) transcript in MCMV. Based on miRNA target predictions, two highly abundant MCMV miRNAs, namely miR-m01-2-3p and miR-M23-2-3p were found to potentially bind to two closely positioned target sites within the IE3 PAR-iCLIP peak. To confirm this hypothesis, we performed luciferase assays and showed that activity values of a luciferase fused with the 3'UTR of IE3 were downregulated in the presence of miR-m01- 2 and miR-M23-2. In a second step, we investigated the effect of pre-expression of miR-m01-2 and miR-M23-2 on the induction of virus replication. After optimizing the transfection procedure by comparing different reagents and conditions, plaque formation was monitored. We could demonstrate that the replication cycle of the wild-type but not of our MCMV mutant that harbored point mutations in both miRNA binding sites within the IE3-3'UTR, was significantly delayed in the presence of miR-m01-2 and miR-M23-2. This confirmed that miR-m01-2 and miR-M23-2 functionally target the major transcription factor IE3 which acts as an indispensable regulator of viral gene expression during MCMV lytic infection. Repression of the major immediate early genes by viral miRNAs is a conserved feature of cytomegaloviruses. The functional role of this type of regulation can now be studied in the MCMV mouse model.
Der Weg von der Entwicklung bis zur Zulassung neuer Virostatika ist bis heute mit hohen Kosten und einem großen Zeitaufwand verbunden. Sollten jedoch bereits zugelassene antivirale Medikamente eine Wirkung auf andere virale Infektionen zeigen, könnte dieser Prozess stark verkürzt werden. Daher war es Ziel dieser Arbeit, den Effekt von zugelassenen Medikamenten, gegen HSV-1, mCMV, hCMV, RSV, Parainfluenzavirus-3, DENV-2, CHIKV, Poliovirus, Masernvirus und HIV-1 zu evaluieren. Getestet wurden die Polymeraseinhibitoren ACV, GCV, CDV, sowie das neuere Medikament T-705 und die reversen Transkriptase-Inhibitoren TDF, 3TC, AZT und ABC. Außerdem die Proteaseinhibitoren SMV, GRV, DCV, LDV, ELB, VEL, SOF und DSV.
TDF senkte in einer Konzentration von 10 µM die Infektiosität von HSV-1 und mCMV bis zu 1 Größenordnung. Auch ABC senkte die Infektiosität von HSV-1 und mCMV in einer Konzentration von 30 µM um 0,4 bzw. 0,6 Größenordnungen. AZT und ELB senkten die Infektiosität bei Infektionen mit HSV-1 in einer Konzentration von 30 µM um 0,4 Größenordnungen. VEL senkte die Infektiosität von mCMV bis zu einer Konzentration von 2 µM um 0,7 Größenordnungen. Durch die Substanzen ELB und LDV konnte die Replikation von DENV-2 bei einer Konzentration von 10 µM um 0,6 bzw. 0,8 Größenordnungen gesenkt werden. Die Substanzen zeigten jedoch keinen Effekt auf Infektionen mit CHIKV und Poliovirus, sodass für beide Substanzen ein virusspezifischer Effekt anzunehmen ist. Es wurde keine Wirkung der Substanzen gegen Infektionen mit Masernvirus, RSV oder Parainfluenzavirus-3 in den Versuchen beobachtet. Es wurde gezeigt, dass die verwendeten Methoden eine schnelle und effektive Möglichkeit darstellen, neue direkt-antivirale Medikamente zu etablieren. Zudem stellen die gefundenen Wirkstoffe eine gute Grundlage als Leitsubstanzen zur Entwicklung neuer Wirkstoffe dar. Weitere Versuche mit Kombinationen der wirksamen Substanzen sollten zur weiteren Therapiefindung durchgeführt werden. Damit hat die vorgelegte Arbeit eine hohe Relevanz für die weitere Forschung.
The genomes of both human cytomegalovirus (HCMV) and murine cytomegalovirus (MCMV) were first sequenced over 20 years ago. Similar to HCMV, the MCMV genome had initially been proposed to harbor ≈170 open reading frames (ORFs). More recently, omics approaches revealed HCMV gene expression to be substantially more complex comprising several hundred viral ORFs. Here, we provide a state-of-the art reannotation of lytic MCMV gene expression based on integrative analysis of a large set of omics data. Our data reveal 365 viral transcription start sites (TiSS) that give rise to 380 and 454 viral transcripts and ORFs, respectively. The latter include 200 small ORFs, some of which represented the most highly expressed viral gene products. By combining TiSS profiling with metabolic RNA labelling and chemical nucleotide conversion sequencing (dSLAM-seq), we provide a detailed picture of the expression kinetics of viral transcription. This not only resulted in the identification of a novel MCMV immediate early transcript encoding the m166.5 ORF, which we termed ie4, but also revealed a group of well-expressed viral transcripts that are induced later than canonical true late genes and contain an initiator element (Inr) but no TATA- or TATT-box in their core promoters. We show that viral upstream ORFs (uORFs) tune gene expression of longer viral ORFs expressed in cis at translational level. Finally, we identify a truncated isoform of the viral NK-cell immune evasin m145 arising from a viral TiSS downstream of the canonical m145 mRNA. Despite being ≈5-fold more abundantly expressed than the canonical m145 protein it was not required for downregulating the NK cell ligand, MULT-I. In summary, our work will pave the way for future mechanistic studies on previously unknown cytomegalovirus gene products in an important virus animal model.